Regdanvimab
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19.
≈ 6 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19.[4] The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion.[7][8] The medicine is given by infusion (drip) into a vein.[4][9]
The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis.[4]
Regdanvimab was authorized for medical use in the European Union in November 2021.[4][5]
Medical uses
edit edit sourceIn the European Union, regdanvimab is indicated for the treatment of adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.[4]
Society and culture
edit edit sourceLegal status
edit edit sourceIn March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started a rolling review of data on regdanvimab.[10][11] In October 2021, the EMA started evaluating an application for marketing authorization for the monoclonal antibody regdanvimab (Regkirona) to treat adults with COVID-19 who do not require supplemental oxygen therapy and who are at increased risk of progressing to severe COVID-19.[12] The applicant is Celltrion Healthcare Hungary Kft.[12] The European Medicines Agency (EMA) concluded that regdanvimab can be used for the treatment of confirmed COVID-19 in adults who do not require supplemental oxygen therapy and who are at high risk of progressing to severe COVID-19.[9]
In November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for regdanvimab (Regkirona) for the treatment of COVID-19.[13][14] The company that applied for authorization of Regkirona is Celltrion Healthcare Hungary Kft.[14] Regdanvimab was authorized for medical use in the European Union in November 2021.[4][5]
Names
edit edit sourceRegdanvimab is the international nonproprietary name (INN).[15]
References
edit edit source- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "AusPAR: Regdanvimab". Therapeutic Goods Administration (TGA). 7 December 2021. Archived from the original on 5 January 2022. Retrieved 4 January 2022. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "TGA Provisional Approval of Celltrion Healthcare Australia Pty Ltd COVID-19 treatment, regdanvimab (Regkirona)". Therapeutic Goods Administration (TGA) (Press release). 6 December 2021. Archived from the original on 5 January 2022. Retrieved 4 January 2022. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ a b c d e f g "Regkirona EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ a b c "Regkirona". Union Register of medicinal products. 12 November 2021. Archived from the original on 24 April 2022. Retrieved 24 April 2022. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform" (Press release). Celltrion. 11 February 2021. Archived from the original on 19 October 2021. Retrieved 4 March 2021 – via Business Wire. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59" (Press release). Celltrion. 13 January 2021. Archived from the original on 19 October 2021. Retrieved 4 March 2021 – via Business Wire. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ a b "EMA issues advice on use of regdanvimab for treating COVID-19". European Medicines Agency. 26 March 2021. Archived from the original on 15 November 2021. Retrieved 15 October 2021. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19" (Press release). European Medicines Agency (EMA). 24 February 2021. Archived from the original on 15 November 2021. Retrieved 4 March 2021. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "EMA review of regdanvimab for COVID-19 to support national decisions on early use" (Press release). European Medicines Agency (EMA). 2 March 2021. Archived from the original on 28 October 2021. Retrieved 4 March 2021. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ a b "EMA receives application for marketing authorisation Regkirona (regdanvimab) treating patients with COVID-19". European Medicines Agency. 4 October 2021. Archived from the original on 11 November 2021. Retrieved 15 October 2021. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "Regkirona: Pending EC decision". European Medicines Agency. 11 November 2021. Archived from the original on 11 November 2021. Retrieved 11 November 2021. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ a b "COVID-19: EMA recommends authorisation of two monoclonal antibody medicines". European Medicines Agency (EMA) (Press release). 11 November 2021. Archived from the original on 13 November 2021. Retrieved 11 November 2021. Wikipedia revision 1338742550, retrieved 2026-11-18
- ^ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85" (PDF). WHO Drug Information. 35 (1). 2021. Archived (PDF) from the original on 19 April 2021. Retrieved 24 April 2022. Wikipedia revision 1338742550, retrieved 2026-11-18
Further reading
edit edit source- Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, et al. (January 2021). "A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein". Nature Communications. 12 (1): 288. doi:10.1038/s41467-020-20602-5. PMC 7803729. PMID 33436577.
- Syed YY (December 2021). "Regdanvimab: First Approval". Drugs. 81 (18): 2133–7. doi:10.1007/s40265-021-01626-7. PMC 8558754. PMID 34724174.
External links
edit edit source- "Regdanvimab". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 24 May 2022.
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338742550 under CC BY-SA 4.0; modifications have been made.